John S. Penn
About
In The Last Decade
John S. Penn
140 papers receiving 6.0k citations
Hit Papers
Peers
Comparison fields: 5 of 153
- Molecular Biology 2.4k
- Radiology, Nuclear Medicine and Imaging 2.3k
- Ophthalmology 2.3k
- Pulmonary and Respiratory Medicine 911
- Pediatrics, Perinatology and Child Health 829
Countries citing papers authored by John S. Penn
This map shows the geographic impact of John S. Penn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John S. Penn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John S. Penn more than expected).
Fields of papers citing papers by John S. Penn
This network shows the impact of papers produced by John S. Penn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John S. Penn. The network helps show where John S. Penn may publish in the future.
Co-authorship network of co-authors of John S. Penn
This figure shows the co-authorship network connecting the top 25 collaborators of John S. Penn. A scholar is included among the top collaborators of John S. Penn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John S. Penn. John S. Penn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 3 | |
| 3 | 2 | |
| 4 | 5,6-epoxyeicosatrienoic acid ethanolamide endocannabinoid mitigates diabetes-induced retinal vascular inflammation | 1 |
| 5 | Cannabinoid Receptor 2 Agonist HU-308 Demonstrates Therapeutic Potential in Inflammatory Diabetic Retinopathy Models | 2 |
| 6 | Characterization of inflammatory cytokine effects on retinal cell NF-kB P65 nuclear translocation and cytokine and cell adhesion molecule expression | 1 |
| 7 | Epoxydocosapentaenoic acid (EDP) and epoxyeicosatrienoic acid (EET) affect TNFα production and leukocyte adhesion in diabetic retinopathy | 1 |
| 8 | GAPDH/Siah1 Signaling Mediates Apoptosis in High Glucose-treated Human Retinal Pericytes | 1 |
| 9 | 24 | |
| 10 | The PGF2 FP Receptor Mediates Retinal Angiogenic Cell Behaviors In Vitro | 1 |
| 11 | Calcium Signaling Inhibitors Reduce Retinal Cell Responses to High Glucose | 1 |
| 12 | Inhibition of Prostaglandins is Associated With Decreased Retinal VEGF Expression Levels in an Animal Model of AMD | 1 |
| 13 | PGE2 Receptor EP4 Is a Potential Therapeutic Target for the Treatment of Pathological Ocular Angiogenesis | 1 |
| 14 | Vascular Endothelial Growth Factor Response to Insulin-Like Growth Factor in Normoxic and Hypoxic Cell Culture | 2 |
| 15 | Hypoxia–Induced COX–2 Translocation: In vivo and in vitro Studies | 1 |
| 16 | The Effect of Anecortave Acetate on VEGF Message and Protein Levels in Hypoxic Müller Cells and in Rat OIR | 2 |
| 17 | Src Family Kinases, New Therapeutic Targets for Intervention of VEGF–Mediated Retinopathy | 1 |
| 18 | Nepafenac Metabolite, Amfenac, Inhibits VEGF Induced Phosphorylation of ERK in Human Retinal Microvascular Endothelial Cells | 3 |
| 19 | Inhibition Of VEGF–Induced Endothelial Cell Poliferation And Differentiation By Steroidal And Non–steroidal Cox Inhibitors With Variable Cox–1/Cox–2 Selectivity | 1 |
| 20 | Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1. | 48 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.